What is Liquidia's latest dividend and current dividend yield?

What were the key takeaways from Liquidia’s earnings call?

What is the market's earnings forecast for Liquidia next quarter?

What does Liquidia do and what are its main business segments?

What is the revenue and EPS growth rate for Liquidia year over year?

What factors drove the changes in Liquidia's revenue and profit?

What guidance did Liquidia's management provide for the next earnings period?

What were the key takeaways from Liquidia's earnings call?

- **Commercial Success**: YUTREPIA achieved 2,000+ prescriptions and 1,500+ patient starts with 85% pull-through rate, outperforming Tyvaso's growth. 
- **Financial Discipline**: $51.7M in sales with positive EBITDA and first positive cash flow month, balancing R&D investment. 
- **Litigation Risk**: Ongoing patent case with potential market exclusion or royalty risks. 
- **Strategic Expansion**: Planning trials in IPF/PPF and advancing L606 for 2026 growth.

**【CEO Summary Section】**
- YUTREPIA achieved 2,000+ unique prescriptions and 1,500+ patient starts. The 85% referral-to-start ratio, with 75% naive patients and 25% transitions from inhaled therapies. Clinical expansion plans include trials for PAH transitioning from oral prostacyclins and exploratory studies in IPF/PPF. The company aims to maintain profitability while investing in R&D, with L606's pivotal RESPIRE study launching in H2 2025.

**【CFO Financial Commentary】**
- Q3 2025 net product sales of $51.7M, with $3.6M net loss but $10.1M non-GAAP adjusted EBITDA. September marked the first month of positive net cash flow ($5M), driven by disciplined cash management. The company expects sustained growth in 2026, balancing reinvestment in R&D with profitability.

**【Q&A Highlights】**
- **Market Access Strength**: 85% pull-through rate, contracts with top 3 commercial payers, and removal of new-to-market blocks. **Litigation Risk**: Ongoing patent infringement case with United Therapeutics, with uncertain remedies (royalty or market exclusion). **Patient Engagement**: 50% voucher usage for 28-day trials, supporting early adoption. **Competitive Dynamics**: YUTREPIA captured 75% of market growth vs. Tyvaso's $14.8M increase, driven by product differentiation.

Liquidia Corporation (LQDA) Q3 2025 Earnings Call Transcript

Product Sales, Net

Service Revenue, Net

LQDA

LQDA fundamentals

You can ask Aime